Heparin-Induced Thrombocytopenia (HIT) in the Direct Oral Anticoagulants (DOAC) Era
Annals of Vascular Surgery · 2024
DOI: 10.1016/j.avsg.2024.05.005 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Vascular Surgery, 2024. Verfasst von Reid C Mahoney und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oregon Health & Science University, Portland, OR. Electronic address: mahonere@ohsu.edu. Hauptthemen laut MEDLINE: Anticoagulants, Heparin, Thrombocytopenia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Heparin-induced thrombocytopenia (HIT) is an uncommon complication of heparin therapy with significant risk for severe morbidity and mortality. We investigated the role and outcome of direct oral anticoagulants (DOACs) for the management of HIT. METHODS: After institutional review board (IRB) approval, a retrospective review was performed identifying all patients with positive HIT serotonin-release assays between 2020 and 2022 at two hospitals. The demographic and clinical variables were collected as follows: initial anticoagulant, dosing and indication, interval before onset of HIT, thrombotic complications, platelet nadir and recovery, direct thrombin inhibitor (DTI) and DOAC usage, and clinical outcomes. RESULTS: 15 patients were included in the study. 8 underwent a vascular procedure, 3 had cardiac surgery, 1 patient had both and was included in both groups, and 5 patients had either noncardiac, nonvascular surgery, or no surgery. 14 patients received unfractionated heparin (93% with therapeutic dosing), and 1 received prophylactic enoxaparin prior to diagnosis of HIT. The average time to diagnosis of HIT was 10.77 days after initial anticoagulation. In-hospital mortality was 27%, related to Covid-19 infection (3/4) and intracranial hemorrhage (1/4). 40% developed thrombosis (67% venous, 33% arterial) after the diagnosis of HIT. 8/11 survivors were discharged on a DOAC. With DOAC therapy, platelet counts rebounded to an average of 265K ( ± 104.6 K) within an average of 2.3 days and 364K ( ± 273.9 K) within 30 days after initiation of a DOAC. No recurrent thrombosis occurred after DOAC administration and only one patient had persistent thrombocytopenia within 30 days. CONCLUSIONS: Mortality and thrombosis (arterial and venous) are common complications in patients diagnosed with HIT. In patients who survive to discharge, DOACs are the most common discharge antithrombotic agent, with low rates of recurrent thrombosis and thrombocytopenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Oregon Health & Science University, Portland, OR. Electronic address: mahonere@ohsu.edu.
- Oregon Health & Science University, Portland, OR.
- Oregon Health & Science University, Portland, OR; Portland VA Medical Center, Portland, OR.
Zitieren
APA
Mahoney, R. C., DeLoughery, T. G., Jung, E., Shalhub, S., & Liem, T. K. (2024). Heparin-Induced Thrombocytopenia (HIT) in the Direct Oral Anticoagulants (DOAC) Era. Annals of Vascular Surgery. https://doi.org/10.1016/j.avsg.2024.05.005
Vancouver
Mahoney RC, DeLoughery TG, Jung E, Shalhub S, Liem TK. Heparin-Induced Thrombocytopenia (HIT) in the Direct Oral Anticoagulants (DOAC) Era. Annals of Vascular Surgery. 2024. doi:10.1016/j.avsg.2024.05.005
BibTeX
@article{Mahoney2024,
author = {Mahoney, Reid C and DeLoughery, Thomas G and Jung, Enjae and Shalhub, Sherene and Liem, Timothy K},
title = {Heparin-Induced Thrombocytopenia (HIT) in the Direct Oral Anticoagulants (DOAC) Era},
journal = {Annals of Vascular Surgery},
year = {2024},
doi = {10.1016/j.avsg.2024.05.005}
}
EUVIMED